Therapeutic Response

ER positive, ERBB2 amplification, and PR negative status confers therapeutic sensitivity to Lapatinib in combination with Trastuzumab in patients with Invasive Breast Carcinoma.

Statements

Source and description

Tyverb (lapatinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized laplatinib in combination with trastuzumab for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy in combination with chemotherapy. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.